Correction to: Updates on cardiovascular outcome trials in diabetes.

Following publication of the original article [1], the authors submitted a corrected version of Table 4 (see below).

Correction to: Cardiovasc Diabetol (2017) 16:128 10.1186/s12933-017-0610-y

Following publication of the original article [1], the authors submitted a corrected version of Table 4 (see below), as the original version contained a mistake.

Table 4

Comparison of outcome results from terminated CVOTs in comparison to placebo

	SAVOR-TIMI53 [1, 2]		EXAMINE [3, 4]		TECOS [5]		ELIXA [6]		EMPA-REG OUTCOME [7]		LEADER [8]
	Class	HR (95% CI)	Class	HR (95% CI)	Class	HR (95% CI)	Class	HR (95% CI)	Class	HR (95% CI)	Class	HR (95% CI)
		p value		p value		p value		p value		p value		p value
Cardiovascular endpoints
Primary composite MACE	CV death, MI, or stroke	1.00 (0.89–1.12)0.99	CV death, MI, or stroke	0.96 (≤ 1.16)0.32	CV death, MI, UA, or stroke	0.98 (0.89–1.08)0.65	CV death, MI, UA, or stroke	1.02 (0.89–1.17)0.81	CV death, MI, or stroke	0.86 (0.74–0.99)0.04a	CV death, MI, or stroke	0.87 (0.78–0.97)0.01
Cardiovascular death	Primary endpoint	1.03 (0.87–1.22)0.72	Primary endpoint	0.79 (0.60–1.04)0.10	Secondary endpoint	1.03 (0.89–1.19)0.71	Primary endpoint	0.98 (0.78–1.22)0.85	Primary endpoint	0.62 (0.49–0.77)< 0.001	Primary endpoint	0.78 (0.66–0.93)0.007
Myocardial infarction	Primary endpoint	0.95 (0.80–1.12)0.52	Primary endpoint	1.08 (0.88–1.33)0.47	Secondary endpoint	0.95 (0.81–1.11)0.49	Primary endpoint	1.03 (0.87–1.22)0.71	Primary endpoint	0.87 (0.70–1.09)0.23	Primary endpoint	0.86 (0.73–1.00)0.046
Stroke	Primary endpoint	1.11 (0.88–1.39)0.38	Primary endpoint	0.91 (0.55–1.50)0.71	Secondary endpoint	0.97 (0.79–1.19)0.76	Primary endpoint	1.12 (0.79–1.58)0.54	Primary endpoint	1.18 (0.89–1.56)0.26	Primary endpoint	0.86 (0.71–1.06)0.16
Hospitalization for unstable angina	Secondary endpoint	1.19 (0.89–1.60)0.24	Secondary endpoint	0.90 (0.60–1.37)0.632	Secondary endpoint	0.90 (0.70–1.16)0.42	Primary endpoint	1.11 (0.47–2.62)0.81	Secondary endpoint	0.99 (0.74–1.34)0.97	Extendedprimary endpoint	0.98 (0.76–1.26)0.87
Hospitalization for heart failure	Secondary endpoint	1.27 (1.07–1.51)0.007	Extended primary endpoint	1.19 (0.90–1.58)0.220	Secondary endpoint	1.00 (0.83–1.20)0.98	Secondary endpoint	0.96 (0.75–1.23)0.75	Secondary endpoint	0.65 (0.50–0.85)0.002	Extendedprimary endpoint	0.87 (0.73–1.05)0.14

aSuperiority test

bAverage across all age ranges

cSevere hypoglycaemia as defined by ADA

dNumber of participants per 1000 patient-years

The original article has been corrected.

References

Leiter LA, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(6):1145–53.

Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76.

Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2015;373(3):232–42.

Pfeffer MA, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

Marso SP, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375(4):311–22

Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

Marso SP, et al. Efficacy and safety of degludec versus glargine in Type 2 diabetes. N Engl J Med. 2017;377(8):723–32.

Neal B, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377(7):644-57.

Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;S2213-8587(17):30309–1.